
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature nature.com/articles/s41586-0… @MDAndersonNews

Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.

Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature nature.com/articles/s41586-0… @MDAndersonNews

Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews). cancerletter.com/trials-and-…

"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa. @US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U @GhayasIssa #EndCancer

Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)

We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews

The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute #Leukemia (AUGMENT-101): brnw.ch/21wM2Yh #leusm

Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JCO…

How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision ashpublications.org/blood/ar…

There’s a little more in the article :)

Steroids.

A pleasure to do this on differentiation syndrome with Eytan and Courtney. A thread 🧵 ashpublications.org/blood/ar…

Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99 Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article

👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL at @EHA_Hematology #EHA2024 A thread 🧵

Asciminib frontline!
Presented at #ASCO24: ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c

Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :)
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: vimeo.com/932607668/63addff7… @MDAndersonNews